Google NASDAQ Short Interest Publication Schedule. It lists Settlement and Dissemination dates through January 2015 and the release is always after 4.
As wrong as I've been predicting short interest, let's try a little over/under for the next report on 12/9 after the market closes. My guess: 15.25M. I was shocked that the short interest increased last time but it's difficult to handicap stupidity.
It's a huge market. They're burning through capital at a good clip and they'll have to go back to the well several time before they're cash flow positive if ever. Do they have products superior to MDXG and how long will it take them and how much equity will they burn through before they're a viable competitor?. MDXG is bought out a long time before you know he answers to the questions.
In a couple of weeks I will no longer own KMP and El Paso as MLPs but will own a C Corp by virtue of Kinder's purchase. I understand why it makes sense and ,in fact, it makes a lot of sense in terms of corp structure and ability to economically raise future capital. Unfortunately, the tax ramifications are painful.
My concern is that MMP, EPD, etc. will eventually face the same kind of issues the Kinder recognized and solved with the buyout. I've always planned to get a step in basis in my estate to solve a huge negative basis issue with these great investments. Now, I'm not so certain. Nothing to do about it but something to consider.
Nice sales growth and margins but is burning a fair amount of cash. Seems like you can wait on this one for the next offering to knock the price down. Also it looks like a candidate for a PIPE which will knock the price down when the buyers sell the stock and keep the warrants. That's not a knock on the product which I know nothing about but a comment on the equity structure and the need to raise cash in a year or so.
It's the SI of financial blogs. Some amateur writes a positive article and the stock goes down 32 cents. I'd just as soon they ignore the company. I wonder if any bulge bracket firm believes its worth picking up coverage of the company. Not sure there's enough upside and available stock at this point to make it worthwhile for them.
You really have to wonder what those fricking idiots at all the MACs are smoking to allow reimbursement of such a demonstrably inferior product like Epifix!! To say nothing of the fricking idiots at the VA (well, they're actually fricking idiots!) but apparently they've been tricked to believe that Epifix actually heals faster and cheaper than the competition. It might be that all these ulcers that are being healed faster and more cheaply have been staged by that evil genius Parker Petit just to sell dead skin.
Since we weren't asked by management which competitor's product we wanted comparative studies made, we'll have to accept the one they provided us. Next time they ask me which product people here want Epifix compared to I'll pass on your suggestion but I suspect they preferred to compare it to the one with the largest market share. They might not be taking their marketing cues from this board.
That's a mystery. I don't have a clue how they determine what can be margined. I margined my last stock in July 1987 and got cured of using margin that October.
Look at my post regarding the comparative study. Those kinds of results will sell product and ultimately make the stock price increase.
MDXG just released a mult-center comparative study of Epifix versus Apligraf - bombed, strafed and bayonetted the living. Had I been one of the Apligraf recipients, I would've sued.
Other than a fan of $8.95 trades and good customer service, I've never heard anyone here or elsewhere praise Schwab's stock analysis. As I've written elsewhere and as others have pointed out, the analysis you're citing is completely quantitative and computer derived. Why pay attention to it? They used to provide Goldman Sachs analysis which was generally informative and accurate but they dropped it.
You're in this until the company's bought so do you really care what Chuck Schwab's computer thinks about your company? If they somehow influenced enough sellers to move this back to 7 or even 8, wouldn't you be a buyer?
I thought with the FDA letter last year, no more marketing of the micronized injectable was permitted but sales were and, in fact, have continued.
I think that's one of those impossible to quantify future benefit the results of which will be seen long after Pete has passed the baby off.
Of course the Organizer in Chief has reached a heck of a deal with the Chinese. We'll reduce our greenhouse emissions by 28% by 2028 while the Chinese will agree to reach their peak greenhouse emissions by 2030. His negotiating skills are only surpassed by his leadership skills.